Travere Therapeutics (TVTX) | Stock Overview & Key Data
Travere Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $21.19
High: $22.24
on September 5, 2025
52 Week Range
Low: $9.44
High: $25.29
on September 5, 2024
on February 11, 2025
All-Time High: $37.04 on August 3, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.9B
EPS
-2.02
P/E Ratio (TTM)
-5.30
Forward P/E
-18.08
P/B Ratio
59.95
PEG Ratio
0.06
Div. Yield
N/A
ROE
-705.73%
Beta
0.791
Debt to Equity
1,220.18
Financial Highlights
Profitability
Gross Margin
98.67%
Operating Margin
-11.05%
Profit Margin
-50.64%
Returns and Earnings
Return on Assets (TTM)
-19.28%
Return on Equity (TTM)
-705.73%
EBITDA
$-120.5M
Net Income (TTM)
$-169.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$3.82
Quarterly Revenue Growth (YoY)
111.50%
Quarterly Earnings Growth (YoY)
111.49%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics TVTX | 1.93B Small-cap | 23.66% | 29.74% | 47.01% | 11.49% | 14.07% | 97.09% | -20.82% | 16.91% |
| Vertex VRTX | 101.56B Large-cap | 1.30% | 5.64% | -10.75% | -19.43% | -2.38% | -15.36% | 35.61% | 53.56% |
| Regeneron REGN | 60.77B Large-cap | -1.26% | 0.61% | 18.70% | -16.56% | -19.83% | -49.33% | -20.84% | 5.26% |
| Adaptive ADPT | 1.98B Small-cap | -2.50% | 16.29% | 30.19% | 60.02% | 107.59% | 200.94% | 44.22% | -68.06% |
| Arcutis ARQT | 2.06B Mid-cap | 10.50% | 11.95% | 26.94% | 16.04% | 17.79% | 65.54% | -16.05% | -26.83% |
| Beam Therapeutics BEAM | 2.11B Mid-cap | 27.63% | 11.66% | 22.82% | -20.03% | -15.47% | -10.42% | -63.69% | -18.60% |
Ownership & Short Interest
Insider Ownership
0.75%
Institutional Ownership
117.25%
Shares Short
12M
Short Ratio
8.47
Short % of Shares Outstanding
13.68%
Average 10-Day Volume
2M
Average 90-Day Volume
2M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is TVTX's 52-week high and low?
- In the last 52 weeks, Travere Therapeutics reached a high of $25.29 (on February 11, 2025) and a low of $9.44 (on September 5, 2024).
- What is the market cap and P/E ratio for TVTX?
- Curious about Travere Therapeutics's size and valuation? Its market capitalization stands at 1.93B. When it comes to valuation, the P/E ratio (trailing twelve months) is -5.30, and the forward P/E (looking ahead) is -18.08.
- Does TVTX pay dividends? If so, what's the yield?
- As for dividends, Travere Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Travere Therapeutics's main competitors or similar companies to consider before investing?
When looking at Travere Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.56B Healthcare Biotechnology -15.36% 35.61% Regeneron
REGN60.77B Healthcare Biotechnology -49.33% -20.84% Adaptive
ADPT1.98B Healthcare Biotechnology 200.94% 44.22% Arcutis
ARQT2.06B Healthcare Biotechnology 65.54% -16.05% Beam Therapeutics
BEAM2.11B Healthcare Biotechnology -10.42% -63.69% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Travere Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Travere Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -705.73%, the Debt to Equity ratio from the most recent quarter is 1,220.18, and its Gross Profit Margin stands at 98.67%.
- What is the recent revenue and earnings growth for TVTX?
- Looking at Travere Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $334M. Compared to the same quarter last year (YoY), quarterly revenue grew by 111.50%, and quarterly earnings saw a YoY growth of 111.49%.
- How much of TVTX stock is held by insiders and institutions?
- Wondering who owns Travere Therapeutics stock? Company insiders (like executives and directors) hold about 0.75% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 117.25%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.